PeptideStack
5.2kquestions
20kanswers
220users

Is 2.4 mg weekly a defensible maintenance dose for a GLP-1 receptor agonist?

Asked 26 Jun 2026Modified 1 min agoViewed 3.6k times
16

Stated plainly: 2.4 mg · a GLP-1 receptor agonist.

I am trying to build something sustainable rather than something thorough that I will abandon.

I have already decided the broad direction; this is about the specifics.

How would you structure this, and what thresholds would you set in advance?

maintenance-dose
maintenance-dose

Staying put: the lowest dose that holds a result, the difference between the maximum studied dose and the maximum useful dose, and what the…

54 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
shareeditfollowflag
KS
askedk_szabo27k2726 Jun 2026
5Same position here, and I held the step rather than escalating. Watching for better advice. – juliette_farnese 9 months ago
4Worth adding whether anything else glucose-lowering is on board. – stopper_core 8 months ago
add a comment

3 Answers

Accepted answer first, then by votes
29

Accepted answer

2.4 mg a week is 0.343 mg a day averaged out and 125 mg over a year — but "defensible" is not a property of the number, it is a property of where the number came from. A maintenance dose is defensible when a trial randomised people to it and reported what happened, and indefensible when it was arrived at by interpolation between two doses that were studied. So the question to ask of 2.4 mg is which arm it corresponds to: if a programme ran 2.4 mg as a maintenance level, there is an efficacy figure, a tolerability figure and a discontinuation rate attached to it. If it sits between two studied levels, everything said about it is extrapolation, and the burden of that is on whoever proposed it. The other half of the arithmetic is supply: at 2.4 mg a week a 10 mg vial is 4.17 weeks and you will need about 13 of them a year, which is worth knowing before the dose is settled rather than after. Maintenance doses are set by a prescriber against an individual; nothing here is medical advice.

Start with what is being maintained — weight, glycaemia or both — because they have different dose-response curves.

Weight is a noisy signal. A rolling four-week average is the instrument; single weigh-ins after a dose reduction will show nothing interpretable.

Gastrointestinal tolerability generally improves on a reduced dose, which is a genuine quality-of-life argument for the search rather than only a cost one.

The counter-regulatory hormonal response to weight loss persists for at least a year after the loss, which is the physiological reason maintenance needs something rather than nothing.

Nothing here is medical advice, and research-use compounds are not approved for human use.

The withdrawal trials answer stopping, not reducing. Different questions.

shareimprove this answerflag
MH
answered · acceptedm_haraldsen21k276 Jul 2026
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
25

The honest answer is that the maintenance dose is individual and that the search for it is slow because the feedback is slow.

If the result deteriorates on a lower dose, returning to the previous one is straightforward and does not require re-titration from the bottom provided the gap has been short.

To be exact about it, the maintenance dose is not necessarily the same a year later, since the counter-regulatory response attenuates slowly if at all.

Gastrointestinal adverse event rates in the trials are dose-related, which supports the tolerability argument for the lowest effective dose.

The lowest dose that holds the result is the answer, and it is individual.

shareimprove this answerflag
UM
answeredu100_marks52k3717 Jul 2026
14

Any reduction takes four to five weeks to express itself, so the search proceeds in months.

The withdrawal trials — STEP-4 and SURMOUNT-4 — established what happens when treatment stops entirely. They did not evaluate dose reduction, so the evidence for a lower maintenance dose is inference rather than data.

It helps to be literal here: maintenance and loss are different endpoints. Loss requires a sustained energy deficit; maintenance requires only that the counter-regulatory drive is offset, and that may need less exposure.

Dose-response for weight in the trial programmes was real but flattening at the upper end, which is consistent with a lower maintenance requirement.

Glycaemic maintenance gives a faster signal than weight maintenance.

edited 2 Aug 2026 by aine_mulcahy — fixed an arithmetic slip in the third paragraph

shareimprove this answerflag
AM
answeredaine_mulcahy28k2729 Jul 2026

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.